BRAF and non-small cell lung carcinoma: Currently, the FDA has approved three BRAF inhibitors to be used alone or in combination with other drugs in patients with BRAF V600E mutations, and the combination of dabrafenib + trametinib has been approved for patients with BRAF V600E mutations in advanced NSCLC (Poulikakos et al. 2022).